Lineage Cell Therapeutics opens new California R&D facility and expands Israel manufacturing site

Tyler Patchen

News Reporter

Last year, Roche and Genentech paid $50 million for licensing rights to Lineage Cell Therapeutics’ OpRegen program, a cell therapy that looks to regenerate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lineage Cell Therapeutics opens new California R&D facility and expands Israel manufacturing site

Tyler Patchen

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Lin­eage Cell Ther­a­peu­tics opens new Cal­i­for­nia R&D fa­cil­i­ty and ex­pands Is­rael man­u­fac­tur­ing site

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lineage Cell Therapeutics opens new California R&D facility and expands Israel manufacturing site